drugset / Trial / NCT02179671
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
Timeline
- Start
- 2014-07-25
- Primary completion
- 2016-06-11
- Completion
- 2016-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Gefitinib | Small molecule | — | — |
| Subject | Osimertinib | Small molecule | — | — |
| Subject | Selumetinib | Small molecule | — | — |
| Subject | Tremelimumab | Monoclonal antibody | — | — |